Menu
Not yet recruiting NCT07161843

Use of QRX3 for Acute Tubular Necrosis Type of Renal Failure in Hospitalized Patients ( QRX-3 in ARF)

Phase II / Phase III Interventional Acute Renal Failure (ARF) Acute Tubular Necrosis

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: QRX-3.
Who it may be relevant to
Registry conditions: Acute Renal Failure (ARF), Acute Tubular Necrosis. Basic parameters: 10 years — 80 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Determine the Efficacy of Investigational Drug QRX-3 in Hospitalized Patients With Acute Tubular Necrosis Pattern of Acute Renal Failure

Overview

Use of QRX-3 in hospitalized patients with pediatric and adult patients with acute tubular necrosis renal failure

Interventions

  • Drug QRX-3
    Combination of QRX-3 with standard therapy will be given to one arm in trial , another arm will receive placebo

Primary outcome measures

  • Rate of change in creatinine glomerular filtration rate [Time frame: 28 days]
Secondary outcome measures (2)
  • daily change in glomerular filtration rate in ml/min [Time frame: 7 days]
  • daily change in cystatin C level in mg/dl [Time frame: 7 days]

Eligibility criteria

Inclusion criteria

  • Hospitalized patients
  • presence of Acute renal failure
  • Nephrologist diagnosis of Acute tubular necrosis or fractional excretion of sodium of >2%
  • willingness to participate

Exclusion criteria

High risk of bleeding Absence of hydronephrosis or obstructive uropathy Absence of baseline dialysis use single kidney status

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Quadruple blind
Primary purpose
Treatment

Study locations

United States · 1 center
  • Neukidney Inc — Rosharon

Identifiers

NCT: NCT07161843 · 0002

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗